ArticleThe Journal of allergy and clinical immunology2020
Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells.
Article in The Journal of allergy and clinical immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 198 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
198 citing papers in PubMed, 5 syntheses or guidelines pooled it, 346 citations in OpenAlex.
- A systematic two-sample and bidirectional MR process highlights a unidirectional genetic causal effect of allergic diseases on COVID-19 infection/severity.Journal of translational medicine · 2024Pooled it
- Causal Association and Shared Genetics Between Asthma and COVID-19.Frontiers in immunology · 2022Pooled it
- The Association between Allergic Rhinitis and COVID-19: A Systematic Review and Meta-Analysis.International journal of clinical practice · 2022Pooled it
- From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses.Respiratory research · 2020Pooled it
- Effect of increased BMI and obesity on the outcome of COVID-19 adult patients: A systematic review and meta-analysis.Diabetes & metabolic syndromePooled it
- A Houttuynia cordata-based Chinese herbal formula improved symptoms of allergic rhinitis during the COVID-19 pandemic.Journal of the Chinese Medical Association : JCMA · 2022Trial
- Impact of comorbid asthma on severity of coronavirus disease (COVID-19).Scientific reports · 2020Trial
- Post-Acute Nasal Expression of ACE2, TMPRSS2, FURIN, and NRP1 in Relation to COVID-19 Severity: A Multicenter Cross-Sectional Study.Diagnostics (Basel, Switzerland) · 2026Article
- Skin as a Potential Entry Point for SARS-CoV-2 Virus.International journal of molecular sciences · 2026Article
- Renin-angiotensin imbalance promotes excessive fibrin deposition through M2 macrophage-derived tissue factor expression in eosinophilic chronic rhinosinusitis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- SKIN AS A POTENTIAL ENTRY POINT FOR SARS-COV-2.bioRxiv : the preprint server for biology · 2026Article
- Association between eosinophil counts and outcomes of severe coronavirus disease 2019 in elderly asthma patients: a prospective cohort study.Journal of thoracic disease · 2025Article
- Multifaceted Roles of IL-26 in Physiological and Pathological Conditions.International journal of molecular sciences · 2025Review
- A retrospective cohort study on the association between allergic rhinitis, sublingual immunotherapy, and COVID-19 symptomatology.Scientific reports · 2025Article
- Expression ofBiomedical reports · 2025Article
- IL-13 protects epithelial cells from SARS-CoV-2 infection by inhibiting ACE2-mediated virus binding and cell entry.ImmunoHorizons · 2025Article
- Impact of nasal and inhaled corticosteroids on SARS-CoV-2 infection susceptibility.The Journal of allergy and clinical immunology · 2025Article
- Asthma programs the transcriptional response of human nasal epithelial cells to SARS-CoV-2 Spike-mediated ACE2 engagement.The Journal of allergy and clinical immunology · 2025Article
- Review
- Type 2 immune responses are associated with less severe COVID-19 in a hospitalized cohort.The journal of allergy and clinical immunology. Global · 2025Article
138 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
backgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has dramatically changed our world, country, communities, and families. There is controversy regarding risk factors for severe COVID-19 disease. It has been suggested that asthma and allergy are not highly represented as comorbid conditions associated with COVID-19.
objectiveOur aim was to extend our work in IL-13 biology to determine whether airway epithelial cell expression of 2 key mediators critical for SARS-CoV-2 infection, namely, angiotensin-converting enzyme 2 (ACE2) and transmembrane protease, serine 2 (TMPRSS2), are modulated by IL-13.
methodsWe determined effects of IL-13 treatment on ACE2 and TMPRSS2 expression ex vivo in primary airway epithelial cells from participants with and without type 2 asthma obtained by bronchoscopy. We also examined expression of ACE2 and TMPRSS2 in 2 data sets containing gene expression data from nasal and airway epithelial cells from children and adults with asthma and allergic rhinitis.
resultsIL-13 significantly reduced ACE2 and increased TMPRSS2 expression ex vivo in airway epithelial cells. In 2 independent data sets, ACE2 expression was significantly reduced and TMPRSS2 expression was significantly increased in the nasal and airway epithelial cells in type 2 asthma and allergic rhinitis. ACE2 expression was significantly negatively associated with type 2 cytokines, whereas TMPRSS2 expression was significantly positively associated with type 2 cytokines.
conclusionIL-13 modulates ACE2 and TMPRSS2 expression in airway epithelial cells in asthma and atopy. This deserves further study with regard to any effects that asthma and atopy may render in the setting of COVID-19 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.